Objective To examine the clinical effect of simultaneous intervention for heart and lung on chronic obstructive pulmonary disease（ COPD） of stationary phase combined with stable angina pectoris with Qi deficiencyblood stasis-phlegm blockade syndrome. Methods Ninety-six COPD stationary phase combined with stable angina pectoris patients with Qi deficiency-blood stasis-phlegm blockade syndrome were randomized into control group

Juhong [Exocarpium Citri Rubrum]tablet group

the Tongxinluo（ 通心络） group and the Ju&Tong group

24 cases in each group. The control group was given western medicine routine therapy. In addition to the treatment of the control group

Juhong tablet 3. 6 g was given to the Juhong tablet group orally

twice each day; Tongxinluo capsule 1. 04 g was given to the Tongxinluo group orally

three times each day; Juhong tablet and Tongxinluo capsule were given to the Ju&Tong group. Each group was treated for 8 weeks. The following intems were compared before and after treatment including the scores of cough

cough up phlegm

dyspnea and St. George’ s Respiratory Questionnaire（ SGRQ）

anginal attacks

durante dolors

nitroglycerin consumption

pulmonary function [including forced expiratory volume in one second（ FEV1） and forced vital capacity（ FVC） ]

as well as the levels of serum C reactive protein（ CRP）

interleukin 1β（ IL-1β） and interleukin 10（ IL-10）. Results After treatment

the scores of cough

cough up phlegm

dyspnea and SGRQ decreased in the Juhong tablet group

the Tongxinluo group and the Ju&Tong group. FEV1 and FVC increased. Anginal attacks

durante dolors

nitroglycerin consumption

as well as the levels of serum CRP

IL-1βand IL-10 decreased. Moreover

the effect of certain indexes in the Ju&Tong group was superior to those in the Juhong tablet group and the Tongxinluo group（ P < 0. 05 or P < 0. 01）. Conclusion Simultaneous intervention for heart and lung might improve clinical symptoms and pulmonary function of COPD stationary phase combined with stable angina pectoris with Qi deficiency-blood stasis-phlegm blockade syndrome patients. Inhibiting chronic persistent inflammation might be one of the important mechanisms.